Cargando…
Biomarkers in the development of individualized treatment regimens for colorectal cancer
INTRODUCTION: Colorectal cancer (CRC) is the third most common and second most deadly malignancy in the world with an estimated 1. 9 million cases and 0.9 million deaths in 2020. The 5-year overall survival for stage I disease is 92% compared to a dismal 11% in stage IV disease. At initial presentat...
Autores principales: | Crutcher, Madison, Waldman, Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749006/ https://www.ncbi.nlm.nih.gov/pubmed/36530921 http://dx.doi.org/10.3389/fmed.2022.1062423 |
Ejemplares similares
-
Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer
por: Huang, Wen-Kuan, et al.
Publicado: (2022) -
Senescence-Associated Molecules and Tumor-Immune-Interactions as Prognostic Biomarkers in Colorectal Cancer
por: Kellers, Franziska, et al.
Publicado: (2022) -
Maximizing Completion of the Two-Dose COVID-19 Vaccine Series with Aid from Infographics
por: Crutcher, Madison, et al.
Publicado: (2021) -
Helicobacter pylori Infection in Geriatric Patients: Current Situation and Treatment Regimens
por: Huang, Qiuyue, et al.
Publicado: (2021) -
Non-steroidal anti-inflammatory drugs and biomarkers: A new paradigm in colorectal cancer
por: Rashid, Gowhar, et al.
Publicado: (2023)